Skip to main content
Signal8
Cavalier Jason profile photo

Jason Cavalier

CIK: 0001883290

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)2 (40.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (40.0%)

Compensation grants

Other (G, F, J, C, D, …)1 (20.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

Lyra Therapeutics, Inc. logo
LYRA

Lyra Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (5 total)

  • Lyra Therapeutics, Inc. logo
    LYRA

    Lyra Therapeutics, Inc.

    Apr 1, 2026
    Disposition(D)
    Direct
    667 shares-
  • Lyra Therapeutics, Inc. logo
    LYRA

    Lyra Therapeutics, Inc.

    Jan 6, 2026
    Sale(S)
    Direct
    769 shares at avg. $3.36$3K
  • Lyra Therapeutics, Inc. logo
    LYRA

    Lyra Therapeutics, Inc.

    Jul 10, 2025
    Sale(S)
    Direct
    684 shares at avg. $8.91$6K
  • Lyra Therapeutics, Inc. logo
    LYRA

    Lyra Therapeutics, Inc.

    Jan 8, 2025
    Award(A)
    Direct
    420K shares-
  • Lyra Therapeutics, Inc. logo
    LYRA

    Lyra Therapeutics, Inc.

    Oct 16, 2024
    Award(A)
    Direct
    100K shares-

1-5 of 5

Jason Cavalier files insider reports with the SEC as Principal Financial Officer of Lyra Therapeutics, Inc. (LYRA). Signal8 holds 5 reported Form 4/5 transactions by Jason Cavalier since Sep 2024. The most recent reported transaction is a disposition to issuer (Form 4 code D) in LYRA, dated Apr 1, 2026.

About Cavalier Jason

Cavalier Jason (SEC CIK 0001883290) files insider reports with the SEC as Principal Financial Officer of Lyra Therapeutics, Inc. (LYRA).

Signal8 holds 5 ownership filings by Cavalier Jason, all Form 4s, filed between Oct 18, 2024 and Apr 3, 2026. Those filings report 5 transactions, from Oct 16, 2024 to Apr 1, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Cavalier Jason's filings is in WATERTOWN, MA.

Recent filings by Cavalier Jason

  • Apr 1, 2026: Disposition to issuer transaction of LYRA shares (Form 4, code D).
  • Jan 6, 2026: Open-market sale of LYRA shares (Form 4, code S).
  • Jul 10, 2025: Open-market sale of LYRA shares (Form 4, code S).
  • Jan 8, 2025: Grant or award of LYRA shares (Form 4, code A).
  • Oct 16, 2024: Grant or award of LYRA shares (Form 4, code A).

Other insiders filing for Lyra Therapeutics, Inc. (LYRA)

How to read Form 4 transaction codes